サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1481921

乳がん治療薬の欧州市場：地域別分析 - 薬物療法別、乳がんタイプ別、流通チャネル別、予測（～2030年）

Europe Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy, Breast Cancer Type, and Distribution Channel

出版日
ページ情報
英文 106 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
乳がん治療薬の欧州市場：地域別分析 - 薬物療法別、乳がんタイプ別、流通チャネル別、予測（～2030年）
出版日: 2024年03月04日
発行: The Insight Partners
ページ情報: 英文 106 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の乳がん治療薬の市場規模は、2022年に84億4,696万米ドルに達し、2022～2030年にかけてCAGR 9.0%で成長し、2030年には168億3,617万米ドルに達すると予測されています。

政府および民間組織からの支援増加が欧州の乳がん治療薬市場を後押し

各国政府は乳がん対策の重要性を認識しており、効果的な治療法へのアクセスを改善するための政策を実施しています。多くの政府や民間団体が乳がん治療薬の研究開発への資金を増やし、その結果、革新的な薬剤や治療法が開発されています。乳がんに関する欧州委員会イニシアティブ（ECIBC）は、あらゆるレベルで普遍的にアクセス可能な基本的な質の高い治療を提供しています。ECIBCの使命は、最新の科学的研究に基づいた検診やケアについて、女性やヘルスケア関係者に公平で偏りのない助言を与えることです。研究への投資が増加したことで、製薬会社は新たな治療法を模索し、乳がん患者のために高度に的を絞った効果的な治療法を開発できるようになりました。

また、世界中のいくつかの政府機関は、乳がん治療薬の費用を患者負担とする償還政策やヘルスケアイニシアチブを実施することにより、これらの治療法へのアクセスを改善するための措置を講じています。このことは、より多くの患者がこれらの治療を受けられるようになり、乳がん治療における最新の進歩を利用できるようになることを意味します。政府の支援が強化されたことで、ヘルスケアプロバイダーにとっても有利な市場環境が生まれました。より多くの資金と資源を利用できるようになったことで、ヘルスケアプロバイダーは患者に幅広い治療選択肢を提供できるようになった。これにより、患者の転帰が改善され、ヘルスケアプロバイダーは市場競争力を維持することができます。全体として、乳がん治療薬に対する政府や民間団体からの支援の増加は、技術革新を促進し、新しい治療法や改善された治療法をもたらしています。また、これらの治療法へのアクセスも改善され、より多くの患者に恩恵をもたらしています。製薬企業やヘルスケアプロバイダーが研究開発活動への投資を継続し、需要の増加に対応するために提供製品を拡大しているため、これは欧州の乳がん治療薬市場の成長にとって大きな機会となっています。

欧州の乳がん治療薬市場の概要

欧州の乳がん治療薬市場は、ドイツ、英国、フランス、イタリア、スペイン、その他の欧州に区分されます。乳がんは英国でよく見られるがんの一種です。国民保健サービス（NHS）のデータでは、英国では女性の約7人に1人が一生の間に乳がんと診断されています。毎年、～5万5,000人の女性が乳がんと診断されています。

乳がん患者を新規治療薬で治療したいという医療産業からの要求が高まっているため、研究開発への投資が拡大し、市場の成長に拍車をかけています。 Breast Cancer Nowは、英国最大の乳がん専門研究助成団体です。現在までに、乳がん患者のためのより良い治療法を開発するための画期的な研究に3億801万米ドル（2億5,000万ポンド）を投資しています。

さらに、政府の努力や市場関係者のイニシアティブが、同国の乳がん治療薬市場の成長を加速させています。2022年11月、NHSは新薬契約を通じて、革新的で命を救う可能性のある乳がん治療薬を発売しました。Pembrolizumab （Keytruda）は化学療法と併用することで、乳がんが進行する可能性をほぼ5分の2に減少させます。Pembrolizumab （Keytruda）は、3～6週間ごとに血流に直接投与され、1年以上継続投与されます。トリプルネガティブ乳がんに対する新薬としては、sacituzumab govitecan（Trodelvy）に次いで2番目のNHSでの販売となります。

欧州の乳がん治療薬市場の収益と2030年までの予測（100万米ドル）

欧州の乳がん治療薬市場のセグメンテーション

欧州の乳がん治療薬市場は、薬物療法、乳がんタイプ、流通チャネルに基づいて細分化されます。

薬物療法に基づき、欧州の乳がん治療薬市場は標的薬物療法、ホルモン薬物療法、化学療法、免疫療法/生物学的療法に区分されます。2022年は標的薬物療法分野が大きなシェアを占めています。標的薬物療法セグメントは2022年に大きなシェアを占めました。標的薬物療法セグメントはさらに、 abemaciclib、ado-trastuzumab emtansine、palbociclib、trastuzumab、その他の標的薬物療法に細分化されます。さらに、ホルモン薬物療法セグメントは、選択的エストロゲン受容体モジュレーター、アロマターゼ阻害剤、選択的エストロゲン受容体ダウンレギュレーターに分類されます。

乳がんタイプ別では、欧州の乳がん治療薬市場はホルモン受容体、HER2+、トリプルネガティブ乳がんに区分されます。2022年にはホルモン受容体セグメントが大きなシェアを占めています。

流通チャネル別では、欧州の乳がん治療薬市場は病院薬局、ドラッグストア・小売薬局、オンライン薬局に区分されます。2022年には病院薬局セグメントが大きなシェアを占めています。

国別では、欧州の乳がん治療薬市場はドイツ、フランス、英国、イタリア、スペイン、その他の欧州に分類されます。2022年の欧州の乳がん治療薬市場は英国が支配的でした。

Eli Lilly and Co、Eisai Co Ltd、Novartis AG、AstraZeneca Plc、Pfizer Inc、Gilead Sciences Inc、Merck & Co Inc、Teva Pharmaceutical Industries Ltd、Amgen Incは、欧州の乳がん治療薬市場で事業を展開している大手企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州の乳がん治療薬市場 - 主要産業力学

  • 主な市場促進要因
    • 乳がんの負担増
    • 複数の診断薬およびスクリーニングプログラムの開始
  • 主な市場抑制要因
    • 診断と治療にかかるコストの高さ
  • 主な市場機会
    • 政府・民間団体からの支援の増加
  • 主な将来動向
    • 個別化医療の利用の増加
  • 影響分析

第5章 乳がん治療薬市場：欧州市場分析

  • 欧州の乳がん治療薬市場の収益、2022～2030年

第6章 欧州の乳がん治療薬市場 - 収益・予測（～2030年）：薬物療法別

  • 欧州の乳がん治療薬市場：収益シェア、薬物療法別（2022年・2030年）
  • 標的薬物療法
  • ホルモン薬物療法
  • 化学療法
  • 免疫療法/生物学的療法

第7章 欧州の乳がん治療薬市場 - 収益・予測（～2030年）：乳がんタイプ別

  • 欧州の乳がん治療薬市場：収益シェア、乳がんタイプ別（2022年・2030年）
  • ホルモン受容体
  • HER2+（ヒト上皮成長因子受容体2）
  • トリプルネガティブ乳がん

第8章 欧州の乳がん治療薬市場 - 収益・予測（～2030年）：流通チャネル別

  • 欧州の乳がん治療薬市場：収益シェア、流通チャネル別（2022年・2030年）
  • 病院薬局
  • ドラッグストア・小売薬局
  • オンライン薬局

第9章 欧州の乳がん治療薬市場：国別分析

  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • その他の欧州

第10章 乳がん治療薬市場 - 産業情勢

  • 乳がん治療薬市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第11章 企業プロファイル

  • Eli Lilly and Co
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc

第12章 付録

図表

List Of Tables

  • Table 1. Europe Breast Cancer Therapeutics Market Segmentation
  • Table 2. Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. UK Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. UK Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. UK Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. UK Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. UK Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Germany Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Germany Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Germany Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Germany Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Germany Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. France Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. France Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. France Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. France Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. France Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Italy Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Italy Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Italy Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. Italy Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. Italy Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. Spain Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. Spain Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. Spain Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Spain Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Spain Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Rest of Europe Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Rest of Europe Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. Rest of Europe Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. Rest of Europe Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. Rest of Europe Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
  • Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
  • Table 36. Glossary of Terms, Breast Cancer Therapeutics Market

List Of Figures

  • Figure 1. Europe Breast Cancer Therapeutics Market Segmentation, By Country
  • Figure 2. Europe Breast Cancer Therapeutics Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
  • Figure 6. Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
  • Figure 11. Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
  • Figure 15. Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Europe Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 19. Europe Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 20. UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 21. Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Growth Strategies in Breast Cancer Therapeutics Market
目次
Product Code: BMIRE00029748

The Europe breast cancer therapeutics market was valued at US$ 8,446.96 million in 2022 and is expected to reach US$ 16,836.17 million by 2030; it is estimated to grow at a CAGR of 9.0% from 2022 to 2030.

Increased Support from Government and Private Organizations Fuels the Europe Breast Cancer Therapeutics Market

Governments of various countries recognize the importance of addressing breast cancer and are implementing policies to improve access to effective treatments. Many governments and private organizations have increased funding for research and development in breast cancer therapeutics, resulting in the development of innovative drugs and therapies. The European Commission Initiative on Breast Cancer (ECIBC) offers universally accessible, basic quality care at all levels. The mission of ECIBC is to give women and healthcare practitioners impartial, unbiased advice on screening and care based on the most recent scientific research. The increased investment in research has allowed pharmaceutical companies to explore new treatment options and develop highly targeted and effective therapies for breast cancer patients.

Several government bodies across the world are also taking steps to improve access to these treatments by implementing reimbursement policies and healthcare initiatives that cover the cost of breast cancer therapeutics for patients. This means that more patients can afford these treatments and have access to the latest advancements in breast cancer therapeutics. The increased government support has also created a favorable market environment for healthcare providers. With more funding and resources available, healthcare providers are able to offer their patients a wider range of treatment options. This improves patient outcomes and allows healthcare providers to stay competitive in the market. Overall, the increased support from governments and private organizations for breast cancer therapeutics has driven innovation, leading to new and improved treatments. It has also improved access to these treatments, benefiting more patients. This presents a significant opportunity for the Europe breast cancer therapeutics market growth as pharmaceutical companies and healthcare providers continue to invest in research and development activities and expand their offerings to meet the growing demand.

Europe Breast Cancer Therapeutics Market Overview

The European breast cancer therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Breast cancer is a common type of cancer in the UK. As per the National Health Service (NHS), about one in seven women are diagnosed with breast cancer during their lifespan in Great Britain data. Each year, ~55,000 women are diagnosed with breast cancer.

Greater demand from the medical industry to treat breast cancer patients with novel therapeutics has led to greater investment in R&D, fueling the growth of the market. Breast Cancer Now is the largest dedicated breast cancer research funder in the UK. To date, it has invested US$ 308.01 million (£250 million) in ground-breaking research to develop better treatment for breast cancer patients.

Additionally, the efforts of government and initiatives taken by market players have helped accelerate the growth of the breast cancer therapeutics market in the country. In November 2022, NHS rolled out an innovative and potentially life-saving breast cancer drug through a new drug deal. Pembrolizumab (Keytruda), combined with chemotherapy, reduces the chances of breast cancer progressing by almost two-fifths. The drug is delivered directly into the bloodstream every three to six weeks for over one year; the NHS funds the treatment to give access to eligible patients. It is the second new drug for triple-negative breast cancer available on the NHS, after sacituzumab govitecan (Trodelvy).

Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Breast Cancer Therapeutics Market Segmentation

The Europe breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the Europe breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the Europe breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the Europe breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the Europe breast cancer therapeutics market is categorized into Germany, France, UK, Italy, Spain, and the Rest of Europe. The UK dominated the Europe breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the Europe breast cancer therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Breast Cancer Therapeutics Market - Key Industry Dynamics

  • 4.1 Key Market Drivers
    • 4.1.1 Growing Burden of Breast Cancer
    • 4.1.2 Launch of Several Diagnostics and Screening Programs
  • 4.2 Key Market Restraints
    • 4.2.1 High Cost of Diagnosis and Treatment
  • 4.3 Key Market Opportunities
    • 4.3.1 Increased Support from Government and Private Organizations
  • 4.4 Key Future Trends
    • 4.4.1 Increasing Use of Personalized Medicine
  • 4.5 Impact Analysis:

5. Breast Cancer Therapeutics Market - Europe Market Analysis

  • 5.1 Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

6. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy

  • 6.1 Overview
  • 6.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
  • 6.3 Targeted Drug Therapy
    • 6.3.1 Overview
    • 6.3.2 Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.1 Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
  • 6.4 Hormonal Drug Therapy
    • 6.4.1 Overview
    • 6.4.2 Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.4.2.1 Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
  • 6.5 Chemotherapy
    • 6.5.1 Overview
    • 6.5.2 Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Immunotherapy/ Biological Therapy
    • 6.6.1 Overview
    • 6.6.2 Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type

  • 7.1 Overview
  • 7.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
  • 7.3 Hormone Receptor
    • 7.3.1 Overview
    • 7.3.2 Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 HER2+ (human epidermal growth factor receptor 2)
    • 7.4.1 Overview
    • 7.4.2 HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Triple-Negative Breast Cancer
    • 7.5.1 Overview
    • 7.5.2 Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 8.1 Overview
  • 8.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Drug Store and Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Online Pharmacies
    • 8.5.1 Overview
    • 8.5.2 Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Breast Cancer Therapeutics Market - Country Analysis

  • 9.1 Europe Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
    • 9.1.1 Overview
    • 9.1.2 Europe Breast Cancer Therapeutics Market, Breakdown, by key Country- Revenue (2022) (US$ Million)
    • 9.1.3 Europe Breast Cancer Therapeutics Market, by Country, 2022 and 2030 (%)
      • 9.1.3.1 UK
        • 9.1.3.1.1 UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.1.2 UK: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.2.1 UK: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.2.2 UK: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.3 UK: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.1.4 UK: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.2 Germany
        • 9.1.3.2.1 Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.2.2 Germany: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.2.1 Germany: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.2.2 Germany: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.3 Germany: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.2.4 Germany: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.3 France
        • 9.1.3.3.1 France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.3.2 France: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.2.1 France: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.2.2 France: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.3 France: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.3.4 France: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.4 Italy
        • 9.1.3.4.1 Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.4.2 Italy: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.4.2.1 Italy: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.4.2.2 Italy: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.4.3 Italy: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.4.4 Italy: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.5 Spain
        • 9.1.3.5.1 Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.5.2 Spain: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.5.2.1 Spain: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.5.2.2 Spain: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.5.3 Spain: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.5.4 Spain: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.6 Rest of Europe
        • 9.1.3.6.1 Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.6.2 Rest of Europe: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.6.2.1 Rest of Europe: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.6.2.2 Rest of Europe: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.6.3 Rest of Europe: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.6.4 Rest of Europe: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Breast Cancer Therapeutics Market-Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in Breast Cancer Therapeutics Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Eli Lilly and Co
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Eisai Co Ltd
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Novartis AG
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 AstraZeneca Plc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Pfizer Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Gilead Sciences Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Merck & Co Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Teva Pharmaceutical Industries Ltd
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Amgen Inc
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms